ArticleCureus2026
Biology Over Imaging: Duodenal Adenocarcinoma Recurrence Presenting as a Pancreatic Head Mass in Lynch Syndrome.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Duodenal adenocarcinoma (DA) is a rare gastrointestinal malignancy with an increased incidence in patients with Lynch syndrome (LS). Although recurrence following resection is recognised, patterns of relapse are typically predictable, most commonly involving the liver, lymph nodes, or peritoneum. Presentation as a pancreatic mass is exceedingly uncommon and poses a significant diagnostic and treatment challenge. We report the case of a 47-year-old man with PMS2-associated LS who underwent curative resection for DA in 2021. Four years later, he presented with a pancreatic head mass that demonstrated radiological features consistent with a locally advanced (LA) primary pancreatic ductal adenocarcinoma (PDAC). Initial clinical and imaging findings strongly supported this diagnosis. The patient underwent six months of neoadjuvant chemotherapy with significant tumour regression, leading to pancreaticoduodenectomy. Unexpectedly, the final histopathological evaluation revealed the lesion to be a recurrence of the original DA rather than a new PDAC. This report highlights a rare and misleading pattern of recurrence in LS, where tumour biology overrides conventional anatomical assumptions. It underscores the importance of maintaining diagnostic vigilance in patients with hereditary cancer syndromes and supports an aggressive, multidisciplinary approach, including neoadjuvant therapy, even in cases initially presumed to represent locally advanced PDAC. Recognition of such atypical presentations is essential not only for optimising management but also for reinforcing the central role of tumour biology in guiding diagnosis, therapeutic decision-making, and future research in hereditary malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.